At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 454 enrolled
Drug / intervention
Pimavanserin +1 moredrug
Likely dose
Pimavanserin 34 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
In Brief
A Phase 3 clinical trial evaluating Pimavanserin and Placebo for Schizophrenia. Completed, enrolled 454 participants across 102 sites in 12 countries.
Detailed Summary
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of negative symptoms of schizophrenia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesArgentina, Bulgaria, Croatia, Czechia, Hungary, Italy, Lithuania, Poland, Russia, Serbia, Spain, Ukraine
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartAug 2020
First PostedAug 2020
Primary CompletionJan 2024
Study CompletionFeb 2024
TodayJul 2026
First PostedAug 31, 2020
Enrollment StartAug 5, 2020
Primary CompletionJan 25, 2024
Study CompletionFeb 19, 2024
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 5.8 years ago
Interventions
Pimavanserindrug
Pimavanserin 34 mg, taken as two blinded 17 mg tablets once daily by mouth
Placebodrug
Placebo, taken as two blinded tablets once daily by mouth